Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial. - Brites C; Montaño-Castellon I; Arriaga MB; Marconi C; Mayoral R; Luz E; Figueredo CA; Fiuza BSD; Netto EM (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026)